AvantGen, Inc. is a premier partner in advancing antibody drugs, specializing in the discovery and optimization of novel antibody drugs. With a dedicated and flexible team, AvantGen provides a platform that has resulted in success for multiple projects, including difficult targets and novel reagents. Their proprietary yeast display system, coupled with their Germliner Library Collection, offers three fully human platforms with over 100 billion antibody clones, known for their high affinity, specificity, thermostability, expression level, and low immunogenicity.
Additionally, AvantGen leverages their expertise in library design and engineered platforms to optimize lead candidates, often improving affinity by 10- to 100-fold. For those interested in nonhuman reagent or diagnostic antibodies, AvantGen utilizes the advantages of the rabbit immune system to provide monoclonal antibodies with superior affinity and specificity. Furthermore, AvantGen has developed a Natural Killer (NK) cell engager platform, boosting the human innate immune system for cancer immunotherapy. Their CD16a antibodies, isolated and developed using their Germliner Library Collection and AvantSabre platform, are available for licensing.
Generated from the website